Skip to main content
. Author manuscript; available in PMC: 2014 May 5.
Published in final edited form as: Prostate. 2013 Jun 15;73(12):1316–1325. doi: 10.1002/pros.22677

Fig. 6.

Fig. 6

Growth response of androgen-dependent PC-82 human prostate cancer xenografts inoculated into immune deficient intact adult male nude mice (n = 10 per group), which were either un treated or supplemented with testosterone implants. Values are the mean ± SEM of the serum TT for the group. PC-82 was originally derived from a primary cancer from a hormonally năve patient with localized disease.